Mfool and seeking alpha are just spewing bs everywhere to get noticed and get people signed up. Pay no attention. They are doing the same thing with aapl everyday. Dwelling on the negative with a purpose. They either want shares or are short. As long as the company performs,the rest will be history. Don't sell your shares cheap.
I've never found MFool informative, and long ago i grew tired of their "articles" acting as mere teasers for subscription solicitations. So, I wouldn't have even seen this article were it not for this Board. It does read like a hit piece written by a guy who did not do his homework.
Good response there by zake1 who, I believe, comments here also.
Motley fool is an adv site and a hedge fund rag.Note the timing and INSM trades.Motley fools guys were good years ago and made a name for themselves.They were bought out and the result is misleading articles
Note most avgs @ 50 day..pivot point GL
Look at the credentials of this "Motley Fool." He has about as much credibility as the "donut eating retired cop" of two years ago who said buy every share you could lay your hands on! The answer is simply in the hands of Will Lewis and the FEV1/log kill data that is being reviewed by Chiltren (and soon by EMEA) and the progress on the NTM. Personally, I still believe there is a 51% chance for expedited FDA review whenever the Phase IIb is closed and the data is reviewed by the FDA. We shall see. But until whenever the data can be made public . . . it is all best guestimate. But this guy was a true blue "Motley Fool." He even said he was considering shorting! A practice that should be either eliminated by SEC or subject to penalty for holding less than 3 months.
I think it's just simple ignorance. If you shorted 10 biotech stocks that have risen 300% over the past 12 months, you would probably make money overall, but his "facts" on Insmed are lacking to say the least! First of all, he didn't even mention Cystic Fibrosis or the EU phase 3 trial, NTM is late in the year. Secondly he is misleading his readers about the time for Arikace potential approval based on EU EMA first and then US approval later. Thirdly, he's basically saying that history will repeat itself with INSM. This completely ignores that Insmed is a completely different company with new leadership and a far different clinical expertise than the one that failed an MMD trial after the US courts took away our ability to sell Iplex for its "approved" condition. I don't respect guys like this, but it's how he makes a living, so what can you say? I'm confident, and believe results are within days, maybe even hours.
Sentiment: Strong Buy